Literature DB >> 17983517

[Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].

Hui-Juan Wu1, Hai-Tao Wu, Dan-Hui Weng, Hui Xing, Yun-Ping Lu, Ding Ma.   

Abstract

OBJECTIVE: To examine expression of PTEN gene in ovarian cancer cisplatin-sensitive cell line OV2008 cells and cisplatin-resistant cell line C13K cells, and evaluate the effect of wild-type PTEN gene on reversing cisplatin-resistance of C13K cells and underlying mechanisms.
METHODS: The expression of PTEN mRNA and protein in OV2008 and C13K cells were detected by semi-quantitative RT-PCR and western blot. Recombinant eukaryotic expression plasmid containing human wild-type PTEN gene was transfected into C13K cells by lipofectamine 2000. The expression of PTEN mRNA was monitored by RT-PCR and the expression of PTEN, protein kinase B (AKT), phospho-AKT (p-AKT) protein were analyzed by western blot in PTEN transfected and untransfected C13K cells. Proliferation and chemosensitivity of cells to cisplatin were measured by methyl thiazolyl tetrazolium (MTT), and cell apoptosis was detected by flow cytometry after treatment with cisplatin.
RESULTS: (1) The expression of PTEN mRNA and protein (1.02 +/- 0.05, 1.02 +/- 0.07) in OV2008 cells were significantly higher than those in C13K cells, which were 0.45 +/- 0.03 and 0.55 +/- 0.03 respectively (P < 0.05). (2) After transfected with PTEN gene for 48 hours, the expression of PTEN mRNA and protein in C13K cells were 2.04 +/- 0.10, 0.94 +/- 0.04 respectively. Compared with C13K cells transfected with empty vector (1.04 +/- 0.04, 0.36 +/- 0.03) and untransfected C13K cells (1.03 +/- 0.05, 0.37 +/- 0.03), the difference was significant respectively (P < 0.01). The expression of p-AKT protein (0.94 +/- 0.07) was lower than those in control groups (1.66 +/- 0.10, 1.68 +/- 0.14; P < 0.05). (3) The 50% inhibition concentration (IC(50)) to cisplatin of C13K cells transfected with PTEN [(7.2 +/- 0.3) micromol/L] was obviously lower than those of empty-vector transfected cells and untransfected cells [(12.7 +/- 0.4), (13.0 +/- 0.3) micromol/L; P < 0.05]. (4) The apoptosis ratio of C13K cells with wild-type PTEN transfection, empty vector transfection and untransfected were (41.7 +/- 0.9)%, (18.6 +/- 0.7)% and (15.3 +/- 0.8)% respectively (P < 0.01).
CONCLUSIONS: PTEN gene plays an important role in ovarian cancer multidrug resistance. Transfection of PTEN could increase the expression of PTEN and restore drug sensitivity to cisplatin in multidrug-resistant human ovarian cancer cell line C13K by decreasing the expression of p-AKT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17983517

Source DB:  PubMed          Journal:  Zhonghua Fu Chan Ke Za Zhi        ISSN: 0529-567X


  4 in total

1.  SLUG is a direct transcriptional repressor of PTEN tumor suppressor.

Authors:  Berna Uygur; Katrina Abramo; Evgenia Leikina; Calvin Vary; Lucy Liaw; Wen-Shu Wu
Journal:  Prostate       Date:  2015-03-01       Impact factor: 4.104

2.  Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.

Authors:  Tan Min Chin; Margaret P Quinlan; Anurag Singh; Lecia V Sequist; Thomas J Lynch; Daniel A Haber; Sreenath V Sharma; Jeffrey Settleman
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

3.  Expression of NF-κB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance.

Authors:  Lili Wang; Chenxu Wang; Shanshan Jin; Donghui Qu; Huanchun Ying
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Chemoresistance is associated with Beclin-1 and PTEN expression in epithelial ovarian cancers.

Authors:  Huanchun Ying; Donghui Qu; Chuan Liu; Tianshu Ying; Jing Lv; Shanshan Jin; Hongying Xu
Journal:  Oncol Lett       Date:  2015-02-10       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.